-
1
-
-
0035724176
-
Psoriasis - -epidemiology and clinical spectrum
-
Christophers E,. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
-
(2001)
Clin Exp Dermatol
, vol.26
, pp. 314-320
-
-
Christophers, E.1
-
2
-
-
70249137988
-
European S3-guidelines on the systemic treatment of psoriasis vulgaris
-
Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1-70.
-
(2009)
J Eur Acad Dermatol Venereol
, vol.23
, pp. 1-70
-
-
Pathirana, D.1
Ormerod, A.D.2
Saiag, P.3
-
3
-
-
71949087471
-
British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009
-
Chair of Guideline Group
-
Smith CH, Anstey AV, Barker JN, et al.; Chair of Guideline Group. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
-
(2009)
Br J Dermatol
, vol.161
, pp. 987-1019
-
-
Smith, C.H.1
Anstey, A.V.2
Barker, J.N.3
-
4
-
-
24344471811
-
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005
-
Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497.
-
(2005)
Br J Dermatol
, vol.153
, pp. 486-497
-
-
Smith, C.H.1
Anstey, A.V.2
Barker, J.N.3
-
5
-
-
3042845754
-
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
-
Nickoloff BJ, Nestle FO,. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-1675.
-
(2004)
J Clin Invest
, vol.113
, pp. 1664-1675
-
-
Nickoloff, B.J.1
Nestle, F.O.2
-
6
-
-
0036145337
-
The immunologic basis for the treatment of psoriasis with new biologic agents
-
Krueger JG,. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
-
(2002)
J Am Acad Dermatol
, vol.46
, pp. 1-23
-
-
Krueger, J.G.1
-
7
-
-
77951529848
-
Therapeutic antibodies for autoimmunity and inflammation
-
Chan AC, Carter PJ,. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-316.
-
(2010)
Nat Rev Immunol
, vol.10
, pp. 301-316
-
-
Chan, A.C.1
Carter, P.J.2
-
9
-
-
0345107256
-
CA novel targeted T-cell modulator, efalizumab, for plaque psoriasis
-
Efalizumab Study Group
-
Lebwohl M, Tyring SK, Hamilton TK, et al.; Efalizumab Study Group. cA novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-2013.
-
(2003)
N Engl J Med
, vol.349
, pp. 2004-2013
-
-
Lebwohl, M.1
Tyring, S.K.2
Hamilton, T.K.3
-
10
-
-
0346515709
-
Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial
-
Efalizumab Study Group
-
Gordon KB, Papp KA, Hamilton TK, et al.; Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073-3080.
-
(2003)
JAMA
, vol.290
, pp. 3073-3080
-
-
Gordon, K.B.1
Papp, K.A.2
Hamilton, T.K.3
-
11
-
-
17144388751
-
Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial
-
Efalizumab Study Group
-
Leonardi CL, Papp KA, Gordon KB, et al.; Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52: 425-433.
-
(2005)
J Am Acad Dermatol
, vol.52
, pp. 425-433
-
-
Leonardi, C.L.1
Papp, K.A.2
Gordon, K.B.3
-
12
-
-
12444336904
-
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
-
Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-38.
-
(2005)
Arch Dermatol
, vol.141
, pp. 31-38
-
-
Menter, A.1
Gordon, K.2
Carey, W.3
-
13
-
-
0344926414
-
Etanercept as monotherapy in patients with psoriasis
-
Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
-
(2003)
N Engl J Med
, vol.349
, pp. 2014-2022
-
-
Leonardi, C.L.1
Powers, J.L.2
Matheson, R.T.3
-
14
-
-
21644481166
-
A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction
-
Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
-
(2005)
Br J Dermatol
, vol.152
, pp. 1304-1312
-
-
Papp, K.A.1
Tyring, S.2
Lahfa, M.3
-
15
-
-
29844440963
-
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial
-
Tyring S, Gottlieb AB, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
-
(2006)
Lancet
, vol.367
, pp. 29-35
-
-
Tyring, S.1
Gottlieb, A.B.2
Papp, K.3
-
16
-
-
0035832515
-
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial
-
Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB,. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.
-
(2001)
Lancet
, vol.357
, pp. 1842-1847
-
-
Chaudhari, U.1
Romano, P.2
Mulcahy, L.D.3
Dooley, L.T.4
Baker, D.G.5
Gottlieb, A.B.6
-
17
-
-
4644327125
-
Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
-
Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542.
-
(2004)
J Am Acad Dermatol
, vol.51
, pp. 534-542
-
-
Gottlieb, A.B.1
Evans, R.2
Li, S.3
-
18
-
-
54249138516
-
Monoclonal antibody pharmacokinetics and pharmacodynamics
-
Wang W, Wang WQ, Balthasar JP,. Monoclonal antibody pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2008; 84: 548-558.
-
(2008)
J Clin Pharm Ther
, vol.84
, pp. 548-558
-
-
Wang, W.1
Wang, W.Q.2
Balthasar, J.P.3
-
19
-
-
42149156689
-
Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness
-
Guttman-Yassky E, Vugmeyster Y, Lowes MA, et al. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol 2008; 128: 1182-1191.
-
(2008)
J Invest Dermatol
, vol.128
, pp. 1182-1191
-
-
Guttman-Yassky, E.1
Vugmeyster, Y.2
Lowes, M.A.3
-
20
-
-
53949099628
-
Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: Results of a randomized, single blind study
-
Krueger JG, Ochs HD, Patel P, et al. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol 2008; 128: 2615-2624.
-
(2008)
J Invest Dermatol
, vol.128
, pp. 2615-2624
-
-
Krueger, J.G.1
Ochs, H.D.2
Patel, P.3
-
21
-
-
84873611070
-
Characterization of immune and asthmatic responses in cynomolgus macaques following antagonism of IL-12/23 activity with ustekinumab (CNTO 1275). Abstract 2141
-
Presented at the Seattle, Washington, US. March 16-20
-
Sachs C, Benson J, Smith P, et al. Characterization of immune and asthmatic responses in cynomolgus macaques following antagonism of IL-12/23 activity with ustekinumab (CNTO 1275). Abstract 2141, presented at the 48th Annual Meeting and ToxExpo of the Society of Toxicology, Seattle, Washington, US. March 16-20, 2008.
-
(2008)
48th Annual Meeting and ToxExpo of the Society of Toxicology
-
-
Sachs, C.1
Benson, J.2
Smith, P.3
-
22
-
-
80054928405
-
-
European Medicines Agency [WWW document] London, 17 April (last accessed: 13 January 2011)
-
European Medicines Agency [WWW document]. Scientific conclusions: Raptiva. London, 17 April 2009. URL (last accessed: 13 January 2011).
-
(2009)
Scientific Conclusions: Raptiva
-
-
-
23
-
-
34548536106
-
The role of dendritic cells in the immunopathogenesis of psoriasis
-
Jariwala SP,. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res 2007; 299: 359-366.
-
(2007)
Arch Dermatol Res
, vol.299
, pp. 359-366
-
-
Jariwala, S.P.1
-
24
-
-
0037313578
-
Interleukin-12 and the regulation of innate resistance and adaptive immunity
-
Trinchieri G,. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat RevImmunol 2003; 3: 133-146.
-
(2003)
Nat RevImmunol
, vol.3
, pp. 133-146
-
-
Trinchieri, G.1
-
25
-
-
34548133583
-
Development, cytokine profile and function of human interleukin 17-producing helper T cells
-
Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-957.
-
(2007)
Nat Immunol
, vol.8
, pp. 950-957
-
-
Wilson, N.J.1
Boniface, K.2
Chan, J.R.3
-
26
-
-
4344605719
-
Current concepts in the immunopathogenesis of psoriasis
-
vii
-
Lowes MA, Lew W, Krueger JG,. Current concepts in the immunopathogenesis of psoriasis. DermatolClin 2004; 22: 349-369, vii.
-
(2004)
DermatolClin
, vol.22
, pp. 349-369
-
-
Lowes, M.A.1
Lew, W.2
Krueger, J.G.3
-
31
-
-
84873609762
-
-
Centocor Ortho Biotech Inc. United States patent US 7560247. 2009 Jul 14
-
Giles-Komar J, et al. Centocor Ortho Biotech Inc. United States patent US 7560247. 2009 Jul 14.
-
(2009)
-
-
Giles-Komar, J.1
-
32
-
-
84873612744
-
-
Abbott GmbH & Co. KG. United States patent US 6914128. Jul 5
-
Salfeld J, et al. Abbott GmbH & Co. KG. United States patent US 6914128. 2007 Jul 5.
-
(2007)
-
-
Salfeld, J.1
-
33
-
-
0003979209
-
-
STE/DoF/Dec2010/EMEA010. Janssen EMEA
-
Data on file. STE/DoF/Dec2010/EMEA010. Janssen EMEA, 2010.
-
(2010)
Data on File
-
-
-
34
-
-
33745804275
-
Biologic therapies for psoriasis: A systematic review
-
Boehncke WH, Prinz J, Gottlieb AB,. Biologic therapies for psoriasis: a systematic review. J Rheumatol 2006; 33: 1447-1451.
-
(2006)
J Rheumatol
, vol.33
, pp. 1447-1451
-
-
Boehncke, W.H.1
Prinz, J.2
Gottlieb, A.B.3
-
35
-
-
43449111187
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
-
PHOENIX 1 study investigators
-
Leonardi CL, Kimball AB, Papp KA, et al.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
-
(2008)
Lancet
, vol.371
, pp. 1665-1674
-
-
Leonardi, C.L.1
Kimball, A.B.2
Papp, K.A.3
-
37
-
-
79953691960
-
Efficacy and safety results from a phase III, randomized controlled trial comparing two dosing regimens of ABT-874 to placebo in patients with moderate to severe psoriasis
-
Poster (P595) presented at the Gothenberg, Sweden. 6-10 October
-
Gordon K, Langley R, Gottlieb A, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing two dosing regimens of ABT-874 to placebo in patients with moderate to severe psoriasis. Poster (P595) presented at the 19th congress of the European Academy of Dermatology and Venerology, Gothenberg, Sweden. 6-10 October, 2010.
-
(2010)
19th Congress of the European Academy of Dermatology and Venerology
-
-
Gordon, K.1
Langley, R.2
Gottlieb, A.3
-
38
-
-
58849118867
-
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis
-
Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009; 49: 162-175.
-
(2009)
J Clin Pharmacol
, vol.49
, pp. 162-175
-
-
Zhu, Y.1
Hu, C.2
Lu, M.3
-
39
-
-
67650670744
-
Briakinumab
-
Lima XT, Abuabara K, Kimball AB, Lima HC,. Briakinumab. Expert Opin Biol Ther 2009; 9: 1107-1113.
-
(2009)
Expert Opin Biol Ther
, vol.9
, pp. 1107-1113
-
-
Lima, X.T.1
Abuabara, K.2
Kimball, A.B.3
Lima, H.C.4
-
40
-
-
34248546506
-
Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes
-
Haider AS, Cardinale IR, Whynot JA, Kruegar JG,. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Invest Dermatol Symp 2007; 12: 9-15.
-
(2007)
J Invest Dermatol Symp
, vol.12
, pp. 9-15
-
-
Haider, A.S.1
Cardinale, I.R.2
Whynot, J.A.3
Kruegar, J.G.4
-
41
-
-
77952722679
-
Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis
-
Langley RG, Strober BE, Gu Y, et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010; 162: 1349-1358.
-
(2010)
Br J Dermatol
, vol.162
, pp. 1349-1358
-
-
Langley, R.G.1
Strober, B.E.2
Gu, Y.3
-
42
-
-
26644433889
-
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial
-
Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
-
(2005)
Lancet
, vol.366
, pp. 1367-1374
-
-
Reich, K.1
Nestle, F.O.2
Papp, K.3
-
43
-
-
32644437923
-
Etanerceptmonotherapy in patients in patients with psoriasis: A summary of safety, based on an integrated multistudy database
-
Gottlieb AB, Leornardi CL, Gofe BS, et al. Etanerceptmonotherapy in patients in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54: S92-S100.
-
(2006)
J Am Acad Dermatol
, vol.54
-
-
Gottlieb, A.B.1
Leornardi, C.L.2
Gofe, B.S.3
-
44
-
-
47549107863
-
Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials
-
Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 274-285.
-
(2008)
Br J Dermatol
, vol.159
, pp. 274-285
-
-
Brimhall, A.K.1
King, L.N.2
Licciardone, J.C.3
-
45
-
-
67650096563
-
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry
-
Research Axed on Tolerance of Biotherapies Group
-
Tubach F, Salmon D, Ravaud P, et al.; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-1894.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 1884-1894
-
-
Tubach, F.1
Salmon, D.2
Ravaud, P.3
-
46
-
-
0036241077
-
Groupe Tuberculose et infliximab. Agence Française de Sécurité Sanitaire de Produits de Santé Recommendations about the prevention and management of tuberculosis in patients taking infliximab
-
GTI and AFSSAPS
-
Salmon D,; GTI and AFSSAPS. Groupe Tuberculose et infliximab. Agence Française de Sécurité Sanitaire de Produits de Santé Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 2002; 69: 170-172.
-
(2002)
Joint Bone Spine
, vol.69
, pp. 170-172
-
-
Salmon, D.1
-
47
-
-
84873611070
-
Absence of developmental toxicity in embryofetal and pre- and postnatal development studies in cynomolgus macaques following antagonism of IL-12/23 activity with ustekinumab (CNTO 1275)
-
Abstract 1160, presented at the Seattle, Washington, US. March 16-20
-
Sachs C, Imai N, Oneda S, et al. Absence of developmental toxicity in embryofetal and pre- and postnatal development studies in cynomolgus macaques following antagonism of IL-12/23 activity with ustekinumab (CNTO 1275). Abstract 1160, presented at the 48th Annual Meeting and ToxExpo of the Society of Toxicology, Seattle, Washington, US. March 16-20, 2008.
-
(2008)
48th Annual Meeting and ToxExpo of the Society of Toxicology
-
-
Sachs, C.1
Imai, N.2
Oneda, S.3
-
48
-
-
25444435193
-
Getting under the skin: The immunogenetics of psoriasis
-
Bowcock AM, Kruegar JB,. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699-710.
-
(2005)
Nat Rev Immunol
, vol.5
, pp. 699-710
-
-
Bowcock, A.M.1
Kruegar, J.B.2
-
49
-
-
40749156754
-
Identification of cellular pathways of 'type 1,' Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis
-
Haider AS, Lowes MA, Suárez-Fariñas M, et al. Identification of cellular pathways of 'type 1,' Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008; 180: 1913-1920.
-
(2008)
J Immunol
, vol.180
, pp. 1913-1920
-
-
Haider, A.S.1
Lowes, M.A.2
Suárez-Fariñas, M.3
-
50
-
-
59849103894
-
New insights into the pathogenesis and genetics of psoriatic arthritis
-
Nograles KE, Brasington RD, Bowcock AM,. New insights into the pathogenesis and genetics of psoriatic arthritis. Rheumatology 2009; 5: 83-91.
-
(2009)
Rheumatology
, vol.5
, pp. 83-91
-
-
Nograles, K.E.1
Brasington, R.D.2
Bowcock, A.M.3
-
51
-
-
37349054996
-
From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis
-
Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008; 58: 94-105.
-
(2008)
J Am Acad Dermatol
, vol.58
, pp. 94-105
-
-
Lebwohl, M.1
Bagel, J.2
Gelfand, J.M.3
-
52
-
-
27444437191
-
The British society for rheumatology biologics register
-
Watson K, Symmons D, Griffiths I, Silman A,. The British society for rheumatology biologics register. Ann Rheum Dis 2005; 64: 42-43.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 42-43
-
-
Watson, K.1
Symmons, D.2
Griffiths, I.3
Silman, A.4
-
53
-
-
52949084362
-
The British society for rheumatology biologics register: 6 years on
-
Symmons DPM on behalf of the BSR Biologics Register
-
Hyrich KL, Watson KD, Isenberg DA,; Symmons DPM on behalf of the BSR Biologics Register. The British society for rheumatology biologics register: 6 years on. Rheumatology 2008; 47: 1441-1443.
-
(2008)
Rheumatology
, vol.47
, pp. 1441-1443
-
-
Hyrich, K.L.1
Watson, K.D.2
Isenberg, D.A.3
-
54
-
-
33744457274
-
Swedish registers to examine drug safety and clinical issues in RA
-
Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006; 65: 707-712.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 707-712
-
-
Askling, J.1
Fored, C.M.2
Geborek, P.3
|